Maxime Lugosi
Overview
Explore the profile of Maxime Lugosi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lefevre G, Bleuse S, Puyade M, Moulis G, Neel A, Abisror N, et al.
Allergy
. 2025 Jan;
PMID: 39757773
Background: Hypereosinophilic syndromes (HES) are a heterogenous group of eosinophilic disorders. To date, only retrospective studies of limited sample-size and/or follow-up duration are available. Methods: The COHESion study is a...
2.
Guerin C, Laramas M, Bettega F, Bocquet A, Berton E, Lugosi M, et al.
Bull Cancer
. 2023 May;
110(7-8):825-835.
PMID: 37225616
Introduction: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment in recent years, but have led to the emergence of new so-called immune-related adverse events (irAE). The objective of this study...
3.
Felix L, Jacon P, Lugosi M, Cristante J, Roux J, Chabre O
Eur Thyroid J
. 2022 Jan;
11(1).
PMID: 34981744
Background And Objective: It has been reported recently in a cross sectional study that patients with amiodarone induced thyrotoxicosis (AIT) showed a 'white' thyroid on unenhanced computed tomography, due to...
4.
Belbezier A, Deroux A, Sarrot-Reynauld F, Colombe B, Bosseray A, Wintenberger C, et al.
J Infect Public Health
. 2020 Apr;
13(7):1047-1050.
PMID: 32224109
Introduction: Hepatitis E virus (HEV) infection has been reported to be associated with neurological disorders. However, the real prevalence of acute hepatitis E in those diseases is still unknown. We...
5.
Gheerbrant H, Giovannini D, Falque L, Andry F, Lugosi M, Deroux A
Presse Med
. 2017 May;
46(5):547-550.
PMID: 28502374
No abstract available.
6.
Adrie C, Lugosi M, Sonneville R, Souweine B, Ruckly S, Cartier J, et al.
Ann Intensive Care
. 2017 Mar;
7(1):30.
PMID: 28303547
Background: Severely ill patients might develop an alteration of their immune system called post-aggressive immunosuppression. We sought to assess the risk of ICU-acquired infection and of mortality according to the...
7.
Gunther S, Schwebel C, Hamidfar-Roy R, Bonadona A, Lugosi M, Ara-Somohano C, et al.
Intensive Care Med
. 2016 Oct;
42(11):1753-1765.
PMID: 27734108
Purpose: To describe all post-insertion complications involving most used intravascular access, and to determine whether the use of a new-generation transparent dressing (3M™ IV Advanced) might reduce their number and...
8.
Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano C, Lugosi M, et al.
Crit Care
. 2015 Aug;
19:287.
PMID: 26283414
Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep venous thrombosis (DVT), is a common and severe complication of critical illness. Although well documented in the general population, the prevalence...
9.
Tolsma V, Schwebel C, Azoulay E, Darmon M, Souweine B, Vesin A, et al.
Chest
. 2014 Jul;
146(5):1205-1213.
PMID: 25033349
Objectives: This study evaluated the influence of the immune profile on the outcome at day 28 (D28) of patients admitted to the ICU for septic shock or severe sepsis. Methods:...
10.
Lugosi M, Alberti C, Zahar J, Garrouste M, Lemiale V, Descorps-Desclere A, et al.
J Infect
. 2014 Jun;
69(3):284-92.
PMID: 24924557
Objectives: To shed light on the meaning of Aspergillus-positive lower-respiratory-tract samples in non immunocompromized critically ill patients. Methods: Multicentre matched case-control (1:5) study. We used prospectively collected data to identify...